Peter Lawson Analyst Performance

US Biotech Equity Analyst - Managing Director at Barclays

Peter Lawson is a stock analyst at Barclays, covering 34 publicly traded companies across a range of sectors. Over the past year, Peter Lawson has issued 22 stock ratings, including buy, hold, and sell recommendations. While full access to Peter Lawson's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Peter Lawson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

77 Last 10 Years

Buy Recommendations

67.53% 52 Buy Ratings

Companies Covered

34 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	67.5%	52 ratings
Hold	29.9%	23 ratings
Sell	2.6%	2 ratings

Out of 77 total stock ratings issued by Peter Lawson at Barclays, the majority (67.5%) have been Buy recommendations, followed by 29.9% Hold and 2.6% Sell.

Best & Worst Calls

• Best Call

  0000.0%

  REPL

  May 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  CLVS

  Jul 2015

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	94.1% of companies on NASDAQ	32 companies
NYSE	2.9% of companies on NYSE	1 company
NYSEAMERICAN	2.9% of companies on NYSEAMERICAN	1 company

Peter Lawson, an analyst at Barclays, currently covers 34 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 32 companies	94.1%
	Miscellaneous 2 companies	5.9%

Peter Lawson of Barclays specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 20 companies	58.8%
PHARMACEUTICAL PREPARATIONS 4 companies	11.8%
MED PRODUCTS 2 companies	5.9%
MED - DRUGS 2 companies	5.9%
Miscellaneous 2 companies	5.9%
MEDICAL INFO SYS 1 company	2.9%
DIAGNOSTIC SUBSTANCES 1 company	2.9%
ANALYTICAL INSTRUMENTS 1 company	2.9%
BIOTECHNOLOGY 1 company	2.9%

Peter Lawson's Ratings History at Barclays

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Time Frame

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
IDYA IDEAYA Biosciences	9/4/2025	Initiated Coverage	$25.76	$40.00	Overweight	$0.00 00.00% ROI
IDYA IDEAYA Biosciences	9/4/2025	Initiated Coverage	$25.83	$40.00	Overweight	$0.00 00.00% ROI
SDGR Schrodinger	8/14/2025	Initiated Coverage	$19.84	$25.00	Overweight	$0.00 00.00% ROI
SDGR Schrodinger	8/14/2025	Initiated Coverage	$19.45	$25.00	Overweight	$0.00 00.00% ROI
REPL Replimune Group	7/23/2025	Downgrade	$2.81	$3.00	Equal Weight	$0.00 00.00% ROI
EXEL Exelixis	7/10/2025	Boost Price Target	$44.75	$40.00	Equal Weight	$0.00 00.00% ROI
MGNX MacroGenics	5/14/2025	Reiterated Rating	$1.54	$3.00	Overweight	$0.00 00.00% ROI
FATE Fate Therapeutics	5/14/2025	Lower Price Target	$0.98	$2.00	Overweight	$0.00 00.00% ROI
ADAP Adaptimmune Therapeutics	5/14/2025	Lower Price Target	$0.28	$0.46	Underweight	$0.00 00.00% ROI
KPTI Karyopharm Therapeutics	5/13/2025	Boost Price Target	$5.30	$10.00	Overweight	$0.00 00.00% ROI
IOVA Iovance Biotherapeutics	5/12/2025	Lower Price Target	$1.81	$4.00	Overweight	$0.00 00.00% ROI
XNCR Xencor	5/8/2025	Lower Price Target	$8.98	$6.00	Underweight	$0.00 00.00% ROI
KURA Kura Oncology	5/2/2025	Lower Price Target	$6.34	$11.00	Overweight	$0.00 00.00% ROI
ARVN Arvinas	5/2/2025	Lower Price Target	$7.08	$16.00	Overweight	$0.00 00.00% ROI
BCYC Bicycle Therapeutics	5/1/2025	Lower Price Target	$9.08	$15.00	Overweight	$0.00 00.00% ROI
SWTX SpringWorks Therapeutics	4/28/2025	Reiterated Rating	$46.18	$47.00	Equal Weight	$0.00 00.00% ROI
RCUS Arcus Biosciences	4/23/2025	Lower Price Target	$8.11	$14.00	Overweight	$0.00 00.00% ROI
IOVA Iovance Biotherapeutics	4/14/2025	Lower Price Target	$3.43	$5.00	Overweight	$0.00 00.00% ROI
BMEA Biomea Fusion	4/2/2025	Lower Price Target	$2.05	$3.00	Equal Weight	$0.00 00.00% ROI
TCRX TScan Therapeutics	3/7/2025	Lower Price Target	$2.08	$3.00	Overweight	$0.00 00.00% ROI
EXEL Exelixis	2/13/2025	Boost Price Target	$33.98	$29.00	Equal Weight	$0.00 00.00% ROI
ARVN Arvinas	2/3/2025	Lower Price Target	$17.61	$32.00	Overweight	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.